For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Allogene Therapeutics, Inc.

USPTO Granted Patents = 20

EPO Patents = 4

Trademarks = 6

Forward Citations = 9

Loading Chart...

Loading Chart...

41 inventors (with patents filed for the assignee):

Barbra Johnson Sasu (12 out of 26 patents)

Thomas John Van Blarcom (11 out of 26 patents)

Siler Panowski (6 out of 11 patents)

4. Thomas Charles Pertel (6 out of 9 patents)

5. Regina Junhui Lin (4 out of 5 patents)

6. Michael Thomas Bethune (4 out of 4 patents)

7. Cesar Adolfo Sommer (3 out of 9 patents)

8. Yi Zhang (3 out of 3 patents)

9. Mark W Leonard (3 out of 3 patents)

10. Eric Hans Gschweng (2 out of 2 patents)

11. Yajin Ni (2 out of 2 patents)

12. Laurent Poirot (1 out of 39 patents)

13. Tao Sai (1 out of 15 patents)

14. Arvind Rajpal (1 out of 47 patents)

15. Meritxell Galindo Casas (1 out of 3 patents)

20 patents: Sort by Forward Citations

1. 12577290 - FASL EXPRESSION AND FASR GENE KNOCKOUT TO PROTECT THERAPEUTIC CELLS FROM ALLOGENEIC REJECTION AND ACTIVATION-INDUCED CELL DEATH (2026-03-17),

2. 12577283 - KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS (2026-03-17),

3. 12528856 - CHIMERIC CYTOKINE RECEPTORS COMPRISING TGF BETA BINDING DOMAINS (2026-01-20),

4. 12447178 - Method of treatment using anti-CD19 rituximab-resistant chimeric antigen receptors (2025-10-21),

5. 12404315 - Protease-activating CD45-gate CAR (2025-09-02),

6. 12365873 - Methods for transducing immune cells (2025-07-22),

7. 12295362 - Formulations and processes for CAR T cell drug products (2025-05-13),

8. 12221462 - Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells (2025-02-11),

9. 12215347 - Chimeric antigen receptors with enhanced signaling and activities and uses thereof (2025-02-04),

10. 12163169 - Inducible chimeric cytokine receptors (2024-12-10),

11. 12163153 - Methods of manufacturing allogeneic CAR T cells (2024-12-10),

12. 12104188 - Modified caspase-9 polypeptides and methods of use thereof (2024-10-01),

13. 12043655 - Constitutively active chimeric cytokine receptors (2024-07-23),

14. 12036243 - BCMA CAR-T cells with enhanced activities (2024-07-16),

15. 11896617 - Polynucleotides encoding rituximab-resistant chimeric antigen receptors (2024-02-13),

Company Overview

Allogene Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, focused on developing allogeneic cell therapies for cancer treatment. The company specializes in harnessing the power of genetically modified T cells to create off-the-shelf therapies that can be administered to patients without the need for personalized cell collection. Allogene's innovative approach aims to improve accessibility and efficacy in cancer care, positioning it as a leader in the evolving field of immuno-oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

20 Patents

#66 in South San Francisco, CA

#3,937 in California

#16,395 in US

#31,264 in the World

South San Francisco, CA, United States of America

Allogene Therapeutics, Inc.

Forward Citations = 9

41 inventors:

Barbra Johnson Sasu (12 out of 26 patents)

Thomas John Van Blarcom (11 out of 26 patents)

Siler Panowski (6 out of 11 patents)

4. Thomas Charles Pertel (6 out of 9 patents)

5. Regina Junhui Lin (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Allogene Therapeutics, Inc.. Retrieved from https://idiyas.com/company/allogene-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…